Gleevec is the drug of choice for Chronic Myeloid Leukemia (or CML) but it doesn’t kill stem cells, leaving some patients at risk for the disease to get worse or relapse, according to Tomasz Skorski, professor of microbiology and immunology at Temple’s School of Medicine. He has found a protein that targets those stem cells in mice. “We think our strategy will be able to eliminate these Gleevec-resistant leukemia cells and eventually cure CML,” he said.